Life changing impact: Reduction in hives

Reduction in hives


reduction in hives
with Xolair® 300 mg vs
baseline at 12 weeks*1,2



of patients were itch-
and hive-free
with Xolair®
300 mg at 12 weeks*1



of patients were
Xolair® 300 mg vs baseline at 12 weeks*‡1


Model is a hypothetical patient profile, for illustrative purposes only

*Data from ASTERIA II; two other phase III studies (ASTERIA I and GLACIAL) were also conducted to assess efficacy and safety of Xolair® in inadequately controlled CSU patients

**Xolair® is also available as a lyophilized formulation

Xolair® 300mg vs. baseline at 12 weeks; p<0.001 vs placebo.

A patient with a UAS7 score of 1-6 will have well-controlled CSU over 7 days4

References: 1. Maurer M, et al. N Engl J Med 2013;368:924-935. 2. Bernstein JA, et al. J Allergy Clin Immunol 2014;133(Suppl 2):AB117 (poster). 3. Xolair® Summary of Product Characteristics 2016.

NP4 code: GLDEIM/IGE025E/0181

Terms of use - Privacy policy - About cookies - Cookie Settings - This site is intended for a global audience.

© 2017 Novartis Pharma